Forty-nine patients with advanced carcinoma of the breast who had received no prior chemotherapy were randomized to receive either high-dose cyclophosphamide (C) 1250 mg/M2 intravenously on day 1 and 5-fluorouracil (F) 600 mg/M2 intravenously on days 1 through 5 (CF), or vincristine (V) 1.5 mg/M2, d
Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer. A randomized trial of the piedmont oncology association
โ Scribed by Hyman B. Muss; Frederick Richards II; Don V. Jackson; M. Robert Cooper; Douglas R. White; John J. Stuart; William Ramseur; Richard M. Christian; H. Bradley Wells; Ellen Pope; Charles L. Spurr
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 538 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Tenfour patients were treated with NFL: mitoxantrone 12 mg/m 2 IV on Day 1; leuconessee. vorin 300 mg IV over 30-60 minutes on Days 1, 2, and 3, immediately preceding
## Background: A prospective, multicenter, randomized, phase iii trial comparing the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (fac) with a combination of vinorelbine and doxorubicin (na) in the treatment of patients with advanced breast carcinoma w